2024 年度内部控制自我评价报告 浙江中欣氟材股份有限公司（以下简称"公司"）董事会根据《企业内部控制 基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称"企业内部 控制规范体系"），结合本公司内部控制制度和评价办法，在内部控制日常监督和 专项监督的基础上，对公司 2024 年 12 月 31 日（内部控制评价报告基准日）的 内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程 ...

证券代码：002915 证券简称：中欣氟材 公告编号：2025-026 浙江中欣氟材股份有限公司 关于召开2024年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江中欣氟材股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开第 六届董事会第二十次会议审议通过了《关于提议召开公司 2024 年年度股东大会 的议案》，决定于 2025 年 5 月 13 日召开公司 2024 年年度股东大会（以下简称"本 次股东大会"）。现将本次股东大会有关事项公告如下： 一、召开会议的基本情况 1、股东大会届次：2024 年年度股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件、深圳证券交易所（以下简称"深交所"）业务规则和 《公司章程》的规定。 4、会议召开时间： （1）现场会议召开时间：2025 年 5 月 13 日（星期二）下午 14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 5 月 13 日 09:1 ...

证券代码：002915 证券简称：中欣氟材 公告编号：2025-010 浙江中欣氟材股份有限公司 第六届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江中欣氟材股份有限公司（以下简称"公司"）第六届监事会第十七次会议 于 2025 年 4 月 18 日在浙江省杭州市拱墅区西湖文化广场 19 号环球中心 2101 会议室以现场表决方式召开。会议通知以书面、邮件或电话方式于 2025 年 3 月 28 日向全体监事发出。应出席监事 3 名，实际出席监事 3 名。 会议由监事会主席俞伟樑先生召集并主持。本次会议的通知、召集和召开符 合《中华人民共和国公司法》（以下简称"《公司法》"）和《浙江中欣氟材股份 有限公司章程》（以下简称"《公司章程》"）的规定，会议决议合法有效。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 具体内容详见公司同日在《证券时报》《证券日报》《中国证券报》《上海证 券报》和巨潮资讯网（http://www.cninfo.com.cn）上披露的《2024 年年度报告》 和《2024 ...

浙江中欣氟材股份有限公司 第六届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：002915 证券简称：中欣氟材 公告编号：2025-009 浙江中欣氟材股份有限公司（以下简称"公司"）第六届董事会第二十次会议 于 2025 年 4 月 18 日在浙江省杭州市拱墅区西湖文化广场 19 号环球中心 2101 会议室以现场结合通讯表决方式召开。会议通知以书面、邮件或电话方式于 2025 年 3 月 28 日向全体董事发出。应出席董事 11 名，实际出席董事 11 名，其中， 董事颜俊文先生以通讯表决的方式出席会议。 会议由董事长徐建国先生召集并主持，公司监事、高级管理人员列席了会议。 本次会议的通知、召集和召开符合《中华人民共和国公司法》（以下简称"《公司 法》"）和《浙江中欣氟材股份有限公司章程》（以下简称"《公司章程》"）的规 定，会议决议合法有效。 二、董事会会议审议情况 （一）审议并通过了《2024 年年度报告及其摘要》 表决结果：同意 11 票，反对 0 票，弃权 0 票。 本议案经公司董事会 ...

浙江中欣氟材股份有限公司 关于2024年度拟不进行利润分配的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2024 年度拟不派发现金红利，不送红股，不以资本公积金转增股本； 证券代码：002915 证券简称：中欣氟材 公告编号：2025-012 会慎重讨论，公司 2024 年度的利润分配方案为：不派发现金红利，不送红股， 不以资本公积金转增股本。 公司 2024 年度业绩出现亏损，不满足进行现金分红的条件，不属于触及《股 票上市规则》第 9.8.1 条第（九）项规定的可能被实施其他风险警示情形。 2、公司不触及《深圳证券交易所股票上市规则》9.8.1 条规定可能被实施其 他风险警示的相关情形。 一、审议程序 浙江中欣氟材股份有限公司（以下简称"中欣氟材"或"公司"）于 2025 年 4 月 18 日分别召开了第六届董事会第二十次会议和第六届监事会第十七次会议， 审议通过了《2024 年度利润分配方案》，并将该方案提交公司 2024 年年度股东 大会审议。 二、利润分配方案的基本情况 经立信会计师事务所（特殊普通合伙）审计，公司 2 ...

证券代码：002915 证券简称：中欣氟材 公告编号：2025-023 浙江中欣氟材股份有限公司 关于提请股东大会授权董事会以简易程序 向特定对象发行股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江中欣氟材股份有限公司（以下简称"中欣氟材"或"公司"）于 2025 年 4 月 18 日分别召开了第六届董事会第二十次会议和第六届监事会第十七次会议，审 议通过了《关于提请股东大会授权董事会以简易程序向特定对象发行股票的议 案》。根据《上市公司证券发行注册管理办法》《深圳证券交易所上市公司证券 发行上市审核规则》《深圳证券交易所上市公司证券发行与承销业务实施细则》 等相关规定，公司董事会提请 2024 年年度股东大会授权董事会办理以简易程序 向特定对象发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20% 的股票，授权期限为公司 2024 年年度股东大会通过之日起至 2025 年年度股东大 会召开之日止。上述事项尚需提交股东大会审议。现将有关情况公告如下： 一、具体内容 （一）确认公司是否符合以简易程序向特定对象发行股票的条件 授权董事会 ...

浙江中欣氟材股份有限公司 2025 年第一季度报告 证券代码：002915 证券简称：中欣氟材 公告编号：2025-025 浙江中欣氟材股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 355,744,197.67 | 317,726,775.95 | 11.97% | | 归属于上市公司股东的净利润 | 3,115,476.97 | 2,553,569.05 | 22.00 ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,404,478,358.56, representing a 4.54% increase compared to CNY 1,343,528,068.38 in 2023[22]. - The net profit attributable to shareholders was a loss of CNY 185,526,314.34 in 2024, a slight improvement of 1.41% from a loss of CNY 188,179,014.98 in 2023[22]. - The cash flow from operating activities improved significantly, with a net outflow of CNY 74,765,694.92 in 2024, a 62.46% reduction from CNY 199,141,335.95 in 2023[22]. - The basic earnings per share for 2024 was -CNY 0.5682, showing a 0.98% improvement from -CNY 0.5738 in 2023[22]. - Total assets at the end of 2024 were CNY 3,193,122,766.38, a marginal increase of 0.06% from CNY 3,191,156,380.44 at the end of 2023[22]. - The company's net assets attributable to shareholders decreased by 12.49% to CNY 1,298,772,126.57 at the end of 2024, down from CNY 1,484,092,908.60 at the end of 2023[22]. - The company reported a significant loss in the fourth quarter, with a net profit attributable to shareholders of -CNY 142,531,581.18[27]. - The company achieved operating revenue of ¥1,404,478,358.56, an increase of 4.54% year-on-year[114]. - The net profit attributable to shareholders was -¥185,526,314.34, a year-on-year reduction in losses of ¥2,652,700.64[114]. Business Operations and Strategy - The company has focused on the production and R&D of fluorine-containing pharmaceutical, pesticide, and electronic material intermediates since its establishment in 2000[20]. - The company operates in the fine chemical manufacturing industry, specifically in the fluorine chemical sector[20]. - The company aims to achieve a 100% phase-out of second-generation refrigerants in the domestic market within the next five years and an 80% phase-out of third-generation refrigerants in developed countries within the next ten years[88]. - The company is actively seeking new markets and customers internationally while solidifying its existing domestic and foreign markets[90]. - The company is committed to developing functional fluorinated new materials and electronic new materials in niche markets[89]. - The company is focusing on the development of new technologies and products in the fluorine chemical sector to enhance its market position[169]. - The company is actively pursuing market expansion and strategic acquisitions to strengthen its competitive edge in the chemical industry[169]. - The company aims to become a leading domestic fluorochemical enterprise with a focus on high-end fluorine materials and a complete industrial chain by the end of 2025[172]. Research and Development - The company has maintained an annual R&D investment of approximately 4% of sales revenue, with a total of 5 invention patents and 13 utility model patents applied for during the reporting period[106]. - The company invested ¥4,309.09 million in R&D in 2024, accounting for 3.07% of total revenue, focusing on new materials and new energy technologies[121]. - The number of R&D personnel rose by 62.16% from 74 in 2023 to 120 in 2024, with a significant increase in the proportion of personnel holding bachelor's degrees by 40%[148]. - The company has developed a new synthesis process for BMMI products, improving yield and quality significantly[100]. - The company is focusing on the development of new energy electronic chemicals, including sodium hexafluorophosphate and lithium bis(fluorosulfonyl)imide, which will significantly enhance product technical content and added value[108]. Market Trends and Industry Outlook - The fluorochemical industry is projected to grow from CNY 178 billion in 2016 to CNY 323 billion by 2025, with a compound annual growth rate of 6.9%[35]. - The pharmaceutical intermediate market in China is expected to reach CNY 255.2 billion in 2024, growing at a rate of 5.45%[39]. - The global market for fluorinated pharmaceutical intermediates has been continuously growing, driven by the increasing number and proportion of fluorinated drugs, particularly in the oncology and antiviral sectors[46]. - The market for fluorinated pesticide intermediates in China reached approximately 12 billion yuan in 2023, with a year-on-year growth of 8%[57]. - The global high-performance polymer market is projected to reach $49.14 billion in 2024, with a compound annual growth rate of 8.4% from 2024 to 2029, indicating strong demand in various industries[58]. Financial Management and Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights[187]. - The company has implemented safety measures to mitigate risks associated with the production of flammable and toxic chemicals, although safety incidents remain a concern[181]. - The company has confirmed that there are no significant discrepancies between its governance practices and regulatory requirements[194]. - The company has established an independent financial accounting department and developed a financial management system compliant with accounting standards[198]. - The company has independent personnel management systems, ensuring that senior management does not hold positions in other companies controlled by the major shareholder[197]. Challenges and Risks - The company faces challenges from high raw material prices and a decline in product prices, impacting gross margins and operating rates[114]. - The company is exposed to raw material price volatility, which significantly affects its operating costs and profit margins[182]. - The company's customer base is concentrated in the pharmaceutical and fluorochemical sectors, with major clients including Jingxin Pharmaceutical and Zhejiang Medicine, which poses a risk if any major client faces operational difficulties[180]. - The company is facing risks related to the concentration of its products in the pharmaceutical and pesticide intermediate sectors, which could impact performance if market conditions change[180]. Environmental and Social Responsibility - The company has invested over 100 million yuan in environmental protection measures, ensuring compliance with national standards for waste emissions[181]. - The company is committed to enhancing investor relations and maintaining a positive capital image through effective communication and transparency[178].

Investment Rating - The report maintains a rating of "Accumulate" for the company [5] Core Views - The company's gross margin is under pressure due to declining product prices and goodwill impairment, leading to a forecasted net profit loss for 2024 [1] - The company is expected to generate revenue between 1.4 billion to 1.42 billion yuan in 2024, with a projected net loss of 200 million to 180 million yuan [1] - The company has a complete fluorochemical industry chain, expanding from traditional pharmaceutical and pesticide sectors to new materials [2] - The recovery in the pesticide industry is anticipated to stabilize product prices and improve profitability [2] - The company’s profitability is expected to gradually recover as downstream demand increases and new production capacities are released [3] Summary by Sections Financial Performance - In 2024, the company is projected to have a revenue of 1.418 billion yuan, a slight increase from 1.344 billion yuan in 2023, but a significant drop in net profit to -192 million yuan [4][8] - The gross margin is expected to decline to 7.7% in 2024 from 13.6% in 2023 [10] - The company’s earnings per share (EPS) is forecasted to be -0.59 yuan in 2024, compared to -0.57 yuan in 2023 [4][10] Production Capacity and Market Outlook - New production capacities for fluorobenzene, fluoroketone, and electronic-grade hydrogen fluoride are expected to come online, but low utilization rates may hinder profitability [1][2] - The company is planning to write down goodwill for its subsidiaries, which will impact overall performance [1] Valuation Metrics - The report projects a decline in net profit for 2024, with subsequent recovery expected in 2025 and 2026, forecasting net profits of 28 million and 75 million yuan respectively [3][4] - The price-to-earnings (P/E) ratio is expected to be 50 in 2026, indicating a potential recovery in profitability [10][11]

Group 1 - The company disclosed that as of February 10, the number of shareholders was 31,292, a decrease of 1,960 from the previous period (January 31), representing a month-on-month decline of 5.89% [1] - On January 18, the company released a 2024 earnings forecast, expecting a net profit loss between 200 million and 180 million yuan [1]